Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

NCT02981914 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Pembrolizumab

Sponsor

University of Chicago